Heart failure & cardiomyopathies
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics
Study context
- Population
- Adults with symptomatic obstructive hypertrophic cardiomyopathy (newly diagnosed or on standard-of-care (SOC) drugs)
- Planned comparison
- Aficamten vs metoprolol
Methodological detailsongoing, Rationale, design and baseline characteristics described; no results reported
- Ongoing
- Rationale, design and baseline characteristics described; no results reported
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics. JACC Heart Fail. doi:10.
Summarised from the published abstract; every number is checked against it